The clinical significance and potential therapeutic role of GPx3 in tumor recurrence after liver transplantation by Lo, CM et al.
Title The clinical significance and potential therapeutic role of GPx3in tumor recurrence after liver transplantation
Author(s) Qi, X; Ng, KTP; Shao, Y; Li, C; Geng, W; Ling, C; Ma, YY; Liu, X;Liu, H; LIU, J; Yeung, WH; Lo, CM; Man, K




Theranostics. Copyright © Ivyspring International Publisher.;
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License.






2016; 6(11): 1934-1946. doi: 10.7150/thno.16023 
Research Paper 
The Clinical Significance and Potential Therapeutic Role 
of GPx3 in Tumor Recurrence after Liver 
Transplantation 
Xiang Qi1, Kevin Tak-Pan Ng1, Yan Shao1, Chang Xian Li1, Wei Geng1, Chang Chun Ling1, Yuen Yuen Ma1, 
Xiao Bing Liu1, Hui Liu1, Jiang Liu1, Wai Ho Yeung1, Chung Mau Lo1,2, Kwan Man1,2  
1. Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong. 
2. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, China.  
 Corresponding author: Prof. Kwan Man; Address: L9-55, Lab Block, 21 Sassoon Road, Pokfulam, Hong Kong; Email: kwanman@hku.hk; Telephone: 
852-39179646; Fax: 852-39179634. 
© Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See 
http://ivyspring.com/terms for terms and conditions. 
Received: 2016.05.01; Accepted: 2016.06.08; Published: 2016.08.08 
Abstract 
Background and Aims: Our previous study showed that small-for-size liver graft may provide favorable 
micro-environment for tumor growth. GPx3, an anti-oxidant, not only attenuates oxidative stress, but 
also suppresses liver tumor growth in our recent study. Here, we aimed to characterize the clinical 
significance and explore the functional role of GPx3 in HCC recurrence after liver transplantation. 
Methods: To explore the association between GPx3 expression and HCC invasiveness, a rat orthotopic 
liver transplantation model with tumor development was established. To investigate the clinical 
relevance of GPx3, 105 HCC patients who underwent liver transplantation were recruited. The 
suppressive role of GPx3 in HCC cells was studied using wound healing, Matrigel invasion assay and lung 
metastasis model. The real-time intravital imaging system was applied to directly visualize the tumor 
cells invasion in a living animal. The underlying mechanism was further explored. 
Results: GPx3 was identified as a down-regulated protein in small-for-size liver graft and significantly 
associated with invasive phenotype of tumor growth in a rat model. Plasma GPx3 was significantly lower 
in small-for-size graft group post-transplantation (day1: 33 vs 1147; day3: 3209 vs 4459; day7: 303 vs 
2506; mU/mL, P<0.05) in rat model. Clinically, the plasma GPx3 was significantly lower in the recipients 
with HCC recurrence post-transplantation (day1: 4.16 vs 8.99 µg/mL, P<0.001; day7: 3.86 vs 9.99 µg/mL, 
P<0.001). Furthermore, lower plasma GPx3 was identified as an independent predictor (HR=4.528, 
P=0.046) for poor overall survival post-transplantation. Over-expression of GPx3 significantly 
suppressed migration, invasiveness and metastasis of HCC cells. Real-time intravital imaging showed 
that GPx3 significantly suppressed HCC invasiveness in a live animal. GPx3 suppressed the tumor 
invasiveness through inhibition of JNK-cJun-MMP2 pathway. 
Conclusion: GPx3 may possess prognostic and therapeutic value for HCC patients after liver 
transplantation. 
Key words: GPx3; HCC invasiveness; intravital imaging; liver transplantation. 
Introduction 
The higher incidence of tumor recurrence after 
living donor liver transplantation (LDLT) compared 
with deceased donor liver transplantation (DDLT) 
was reported in hepatocellular carcinoma (HCC) 
patients [1-4]. The liver grafts from living donor are 
always small-for-size for adult recipients. From our 
previous publication [5, 6], both of our clinical and 
animal studies showed that small-for-size liver graft 
provides favorable environment for tumor recurrence 
after transplantation. Recently, we also demonstrated 
that GPx3, an anti-oxidant, not only attenuates 








growth [7]. In our preliminary study, we found that 
GPx3 was significantly down-regulated in 
small-for-size liver graft, in which more invasive 
tumor cells were observed. Thus, down-regulation of 
GPx3 may be one of the reasons for more aggressive 
tumor behavior in small-for-size liver graft. Based on 
those findings, we hypothesize that GPx3 may 
possess prognostic and therapeutic value in tumor 
recurrence after liver transplantation, especially for 
transplantation using a small-for-size liver graft. 
Therefore, Investigation of the clinical significance of 
GPx3 on tumor recurrence after transplantation, and 
exploration of the suppressive role of GPx3 in HCC 
invasiveness, may help for developing novel 
therapeutic strategy targeting at HCC recurrence after 
liver transplantation. 
Glutathione peroxidase 3 (GPx3) is a 
selenium-dependent enzyme which functions in 
detoxification of reactive oxygen species (ROS) to 
protect the organ from overwhelming oxidative stress 
[8]. It catalyzes the reduction of hydrogen peroxidase, 
organic peroxidase and lipid peroxidase by reduced 
glutathione. According to the reports, GPx3 are 
always down-regulated in several types of cancer due 
to genomic deletion or epigenetic alteration, such as 
prostate cancer [9], gastric cancer [10] and Barrett's 
adenocarcinoma [11]. Moreover, the circulating GPx3 
was identified to be significantly lower in the patients 
with glioblastoma compared with non-tumor patients 
[12]. Furthermore, our previous study has shown that 
GPx3 suppressed the proliferation of HCC cells [7]. 
The role of GPx3 in HCC invasiveness needs further 
exploration. 
With the development of imaging technology, 
the modality of molecular intravital imaging currently 
enables us to directly see the tumor cells in a live 
animal. Optical technique of functional imaging has 
well developed in clinical situation, including 
magnetic resonance imaging (MRI), positron emission 
tomography (PET) or computed tomography (CT). 
However, the major challenge in such technique is the 
limited penetration depth imposed by tissue 
turbidity, which avoids the possibility of utilizing 
high resolution microscope [13]. Here, we utilized a 
novel in vivo imaging system using dorsal window 
chamber which could overcome such limitation. The 
intravital imaging of dorsal window chamber has 
been already applied in detection of vascularization 
with the advantages of dynamically observation and 
high resolution in animal model [14]. The 
establishment of new platform of imaging would 
allow us to observe the tumor behavior with high 
resolution in a live animal. 
In the current study, we aimed to explore the 
prognostic role and therapeutic value of GPx3 on 
tumor recurrence after liver transplantation for HCC 
patients. We firstly studied the association between 
GPx3 expression and HCC invasiveness in a rat 
orthotopic liver transplantation model. Then we 
investigated the clinical significance of GPx3 in HCC 
patients after liver transplantation. After that, we 
examined the functional role of GPx3 in HCC 
invasiveness and further explored the underlying 
mechanism. We hoped that our study could provide 
evidences to explore novel therapeutic strategy 
targeting at HCC recurrence after liver 
transplantation.  
Material and Methods 
Study design 
The study consisted of three parts. In the first 
part, the association between GPx3 expression and 
aggressiveness of liver cancer was investigated in a rat 
orthotopic liver transplantation model and further 
validated in clinical samples (Figure S1A). In the 
second part, the tumor suppressive effect of GPx3 on 
tumor invasiveness and metastasis will be studied in 
vitro and in vivo (Figure S1B). In the third part, the 
underlying mechanisms of anti-invasiveness effect of 
GPx3 will be further explored in HCC cells and 
validated in clinical samples and animal model 
(Figure S1C). 
Clinical specimens 
The study was approved by the Institutional 
Review Board of the University of Hong Kong / 
Hospital Authority Hong Kong West Cluster. One 
hundred and five HCC patients who had undergone 
liver transplantation between December 2000 and 
May 2010 were recruited from Department of 
Surgery, Queen Marry Hospital, The University of 
Hong Kong. The plasma samples at different time 
points were collected from recipients and stored at 
-80ºC. The plasma level of human GPx3 was detected 
using ELISA Kit (AdipoGen Inc, Korea) according to 
instruction manual. The median age of the recipients 
was 54 (30-67) years old. Meanwhile, the median age 
of the donors was 38 (18-71) years old. The median of 
follow up time is 5 years (3 months – 10 years). 
Ninety-two recipients (87%) were male and 64 donors 
(61%) were female. Seventy-two donor grafts (68%) 
were small-for-size (the graft radio ≤ 60%). 
Seventy-nine liver grafts (75%) were from living 
donors. The study was approved by the Ethics 
Committee of the University of Hong Kong. 
Rat Liver Transplantation models 
Male inbred Buffalo rats (body weight: 300-350g) 
were used as donors and recipients for 
transplantation. All the rats were kept with access to 




water and chow in a standard animal laboratory. They 
were housed with a 12-hour light/dark cycle and 
fasted 12 hours before transplantation. All operations 
were performed under clean conditions. The study 
had been licensed according to Animal (Control of 
Experiments) Ordinance Chapter 340 by the 
Department of Health, Hong Kong Special 
Administrative Region. (ref.: (11–632) in 
DH/HA&P/8/2/3 Pt. 31). 
A rat non-arterialized orthotopic liver 
transplantation model was established using whole 
graft and small-for-size graft as donors [4, 5]. Briefly, 
the recipients were injected with a rat hepatoma cell 
line (McA-RH7777, 2×105/200 μL) via the portal vein 
after reperfusion to mimic the clinical situation of 
remained tumor cells in circulation homing to the 
liver graft. The median graft ratio in small-for-size 
graft group (the ratio of graft weight to recipient liver 
weight) was 55% (48-60%). The rats were sacrificed at 
days 1, 3, 7, 14 and 21 after transplantation for 
collecting liver tissues and blood samples. Liver 
tumor tissues and adjacent non-tumor tissues were 
collected at days 14 and 21 post-transplantation.  
Identification of proteomic expression profile 
by 2-dimensional electrophoresis (2-DE) and 
Mass spectrometry (MS) 
The whole blood samples were obtained from 
caudal vein of rats and collected into vacutainer 
containing EDTA. After centrifuged at 3000 rpm for 
10 min, the plasma could be separated and stored at 
-80ºC for further investigation. In first dimension 
electrophoresis, 400μg plasma samples were loaded 
onto linear immortalized pH gradient (IPG) strips (pH 
3-10 L, 240×3×0.5 mm3, BioRad) without any 
pretreatment. The second dimension was performed 
on 12% SDS-PAGE in a protean-plus DodecaTM Cell 
(BioRad). After visualized by silver-staining 
technique, the differential protein spots were excised 
using biopsy punches and transferred to 1.5mL 
Eppendorf tube for Mass-spectrometry (MS) analysis 
using Ultraflex 2 TOF/TOF mass spectrometer 
(Bruker Daltonics).  
Real time quantitative reverse transcription 
polymerize chain reaction (qRT-PCR) and 
Western-blot 
The expression level of GPx3 was detected by 
qRT-PCR and Western-blot as previously described 
[7, 15, 16]. 
Immunohistochemistry (IHC) staining 
Sections of paraffin-embedded tissue (4 μm) 
were stained as previously described [17]. For 
quantification, the sections of each tumor were 
evaluated independently by two different 
investigators. The intensity of immunostaining was 
scored as: weak (1), moderate (2), strong (3) and 
extremely strong (4). An immunohistochemistry score 
(ranging from 0 to 4) was calculated as follows: 
(staining intensity × percentage of positively labeled 
cells) / 100. 
Enzyme-linked immunosorbent assay (ELISA) 
and GPx3 enzyme activity assay 
The plasma samples of clinical patients were 
tested by ELISA [18] and the rat plasma level of GPx3 
was detected by enzyme activity assay as previously 
described [7].  
Construction of stable HCC cell line with 
over-expression of GPx3 
MHCC97L was transduced with full-length 
human GPx3 gene as previously described [7]. 
Wound healing assay and Matrigel invasion 
assay 
To investigate the migration of HCC cells, 
wound healing assay was performed as previously 
described [19]. To examine the invasiveness of HCC 
cells, Matrigel invasion assay was performed as 
previously described [4, 19]. 
Nude mice orthotopic liver cancer model  
We implanted the tumor tissue cubes into the left 
liver lobes of nude mice as described previously [20].  
Real-time intravital imaging using dorsal 
window chamber 
The dorsal window chamber (DWC) consists of 
two titanium frames that marry together to form a 
saddle on the back of the nude mouse and is attached 
using spacers, bolts and fastening nuts. A ‘chamber‘ is 
formed after a transparent glass cover slip placed onto 
the attached saddle covering the exposed fascia 
containing vessels and secured using a sterile 
removable ‘C’ clip. The nude mice ectopic liver cancer 
model was established using liver cancer cells 
(MHCC97L). MHCC97L cells were labeled with 
fluorescence reporter (GFP) during transduction and 
then injected subcutaneously into the window 
chamber from the opposing side to the glass 
cover-slip. The tissue structure surrounding the 
tumor nodule, such as collagen, would be visualized 
through two photons secondary harmonic generation. 
The process of cancer cells invasiveness and 
metastasis would be kinetically observed through 
3D-images reconstruction under CZ LSM 710 confocal 
system. The excitation wavelength was 800nm 
(two-photon system). The emission wave lengths of 
GFP from tumor cells were 500-550nm. The emission 




wave lengths from connective tissue were 385-425nm. 
The objective lens was 20×. 
Lung metastasis model with tumor cells 
injection via tail vein 
The nude mice were assigned into two groups. 
The liver cancer cell lines MHCC97L-pCDH or 
MHCC97L-pCDH-GPx3 (2×106/100µl PBS) were 
injected through tail vein in each group. The mice 
with lung metastasis were visualized using in vivo 
imaging system (Perkin Elmer IVIS Spectrum). The 
background fluorescence noises could be 
distinguished from the positive signals through 
unmixing process. The lung metastasis will be finally 
confirmed by HE staining of tissue sections when the 
nude mice are sacrificed. 
Statistical analysis  
The Chi-square test was used to compare 
categorical data. Paired or unpaired T test were 
adopted to compare continuous variables. The 
median of plasma GPx3 was set as cut-off point by 
with all the patients were segregated into two groups: 
plasma GPx3 high and low group. Kaplan-Meier 
survival analysis was performed to compare the 
survival outcome of HCC patients. The significant 
difference between survival outcomes was detected 
by log–rank test. Cox proportional hazard regression 
model was used to identify predictors for overall 
survival. The variables were selected into final 
equation in multivariable analysis according to 
forward stepwise selection procedure. P < 0.05 was 
considered as statistically significant. Calculation was 
made using SPSS computer software version 16 (SPSS 
Inc, Chicago, IL, USA). 
Results 
GPx3 was identified as a down-regulated 
protein in small-for-size liver graft in a rat liver 
transplantation model with tumor 
development 
Our previous study showed that small-for-size 
liver graft provides favorable micro-environment for 
tumor growth [5, 6]. In the current study, we 
identified that GPx3 was significantly 
down-regulated in small-for-size liver graft in a rat 
orthotopic liver transplantation model (Table S1). 
Recently, we also demonstrated that GPx3 not only 
attenuates oxidative stress, but also suppresses the 
tumor growth in our recent study [7]. Therefore, GPx3 
was selected for the further investigation in the 
current study. Other potential protein candidates are 
being tested. 
Invasive tumor growth was associated with 
down-regulation of GPx3 in small-for-size liver 
graft  
The down-regulation of GPx3 in small-for-size 
liver graft was further confirmed in another 
independent set of animal samples. Plasma GPx3 was 
significantly lower in small-for-size graft group 
compared with whole graft group at different time 
points after liver transplantation (Figure 1A). The 
same trend of the kinetic change of GPx3 expression 
was also observed in intra-graft GPx3 expression 
(Figure 1B). The expression of GPx3 within tumor 
tissues was significantly down-regulated in 
small-for-size graft in both mRNA (Figure 1C) and 
protein level (Figure 1D). Tumor cells were more 
invasive in small-for-size liver graft in which the GPx3 
was confirmed to be down-regulated (Figure 1E and 
1F). It implied that down-regulation of GPx3 might be 
associated with tumor invasiveness in small-for-size 
liver graft. 
Lower plasma GPx3 was correlated with more 
recurrence and poor survival of HCC patients 
after liver transplantation 
In order to explore the clinical significance of 
GPx3, 105 HCC patients who had undergone liver 
transplantation were recruited in our study. Plasma 
GPx3 was significantly lower in the HCC recipients 
with tumor recurrence after liver transplantation 
(Figure 2A). Moreover, plasma GPx3 was also 
correlated with graft size. The lower plasma GPx3 at 
day 1 post-transplantation was mainly observed in 
the patients with small-for-size liver graft (Figure 2B). 
The median of plasma GPx3 was selected as the 
cut-off point, by which all the patients were 
segregated into two groups: plasma GPx3 high group 
and low group. The patients with lower plasma GPx3 
had both significantly poorer overall survival and 
disease free survival (Figure 2C and 2D). Mean 
estimated survival time of the patients with lower 
plasma GPx3 at day 1 post-transplantation was 
significantly shorter compared to those with higher 
GPx3 (67.42±6.89 vs 105.57±3.35 months for overall 
survival; 55.21±8.26 vs 102.88±4.08 months for disease 
free survival). Mean estimated survival time of the 
patients with lower plasma GPx3 at day 7 
post-transplantation was also significantly shorter 
compared with higher GPx3 group (77.26±7.45 vs 
101.06±5.62 months for overall survival; 63.64±8.55 vs 
95.63±6.99 months for disease free survival). 





Figure 1. Expression of GPx3 was significantly down-regulated in small-for-size liver graft in which tumor cells were more invasive. (A) Plasma GPx3 was significantly lower at 
different time points post-transplantation in small-for-size liver graft compared with whole graft, P < 0.05. The error bar represented as mean ± SD. (B) Intra-graft GPx3 
expression was also significantly down-regulated in small-for-size grafts compared with whole grafts, P < 0.05. The error bar represented as mean ± SD. Expression of GPx3 was 
significantly down-regulated within tumor tissues in small-for-size graft in (C) mRNA and (D) protein level. (E) H&E staining showed that tumor cells were more invasive in 
small-for-size liver graft. (F) IHC staining showed intra-hepatic spread of tumor nodules in small-for-size liver graft in which GPx3 was significantly down-regulated. 





Figure 2. Lower plasma GPx3 significantly correlated with more recurrence and poor survival of HCC patients after liver transplantation. (A) Plasma GPx3 was significantly 
lower in the recipients with tumor recurrence after liver transplantation, P < 0.05. The error bar represented as mean ± SD. (B) Lower plasma GPx3 at day 1 post-transplantation 
significantly correlated with small graft size, P < 0.05. The error bar represented as mean ± SD. Lower plasma GPx3 significantly correlated with (C) poor overall survival and (D) 
poor disease free survival of HCC patients’ post-transplantation. The case number depended on the availability of clinical samples. 




Lower plasma GPx3 was identified as an 
independent predictor for poor overall survival 
of HCC patients after liver transplantation 
The independent predictor for overall survival 
was further identified by Cox proportional hazard 
regression analysis (Table 1). In univariable analysis, 
lower plasma GPx3 at day 1 post-transplantation 
(HR=7.237, 95%CI: 2.416-21.676, P=0.000), lower 
plasma GPx3 at day 7 post-transplantation (HR=3.240, 
95%CI: 1.152-9.115, P=0.026), beyond UCSF criteria 
(HR=2.585, 95%CI: 1.151-5.802, P=0.021), higher 
number of tumor nodules (HR=2.660, 95%CI: 
1.163-6.086, P=0.020) were all significantly associated 
with poor overall survival. Other conventional 
prognostic factors, such as higher AFP, beyond Milan 
criteria, larger tumor size and venous infiltration, 
were not significantly associated with overall survival 
(Table S2). Most importantly, in multivariable 
analysis, only plasma GPx3 at day 1 
post-transplantation (HR=4.528, 95%CI: 1.026-19.988, 
P=0.046) was identified as an independent predictor 
for overall survival of HCC patients (Table 1).  
Table 1: Cox proportional hazard regression model for overall 
survival analysis. 
 Univariable analysis Multivariable analysis 
 HR(95%CI) P HR(95%CI) P 
Plasma GPx3 (Day 1)     
Low vs High level 7.237 (2.416-21.676) 0.000* 4.528 (1.026-19.988) 0.046* 
Plasma GPx3 (Day 7)     
Low vs High level 3.240 (1.152-9.115) 0.026* 1.008 (0.285-3.568) 0.991 
UCSF criteria     
Beyond vs Within 2.585 (1.151-5.802) 0.021* 0.520 (0.069-3.943) 0.527 
Number of tumor nodules    
≥3 vs <3 2.660 (1.163-6.086) 0.020* 3.048 (0.422-22.023) 0.269 
HR: Hazard ratio. CI: Confidence interval. *P<0.05. 
Over-expression of GPx3 significantly 
suppressed migration, invasiveness and 
metastasis of HCC cells 
In order to explore the functional role of GPx3 in 
liver cancer, HCC cell line (MHCC97L) with stable 
over-expression of GPx3 was established (Figure S2). 
Although over-expression of GPx3 had little effect on 
the migration of HCC cells in wound healing assay 
(Figure 3A and S3), it significantly inhibited the 
invasiveness of HCC cells in Matrigel invasion assay 
(Figure 3B). It implied that GPx3 suppressed HCC 
invasion through suppressing degradation of 
extracellular matrix, but not through suppressing 
migration of HCC cells. Moreover, in order to explore 
the effect of GPx3 on HCC invasiveness, we 
established the orthotopic nude mice liver cancer 
model. Five weeks after the tumor implantation, the 
animals were sacrificed for samples collection and 
further analysis. We observed that the 
over-expression of GPx3 significantly suppressed 
intra-hepatic spread of tumor cells (Figure 3C, left 
panel). H&E staining showed that more metastatic 
tumor nodules were observed in the control group 
compared with GPx3 over-expression group (Figure 
3C, right panel). Furthermore, the lung metastasis was 
significantly inhibited by over-expression of GPx3 in 
nude mice lung metastasis model (Figure 3D). 
Over-expression of GPx3 significantly 
suppressed HCC invasiveness in a living animal 
by real-time intravital imaging 
In order to investigate the suppressive role of 
GPx3 in HCC invasiveness in vivo, the ectopic nude 
mice liver cancer model with dorsal window chamber 
was established (Figure 4A). The real-time intravital 
images were captured through the dorsal window 
chamber under confocal microscope. This intravital 
imaging platform enabled us to kinetically observe 
the tumor behavior and directly see the tumor cells in 
a living animal. We found that over-expression of 
GPx3 significantly suppressed HCC invasiveness at 
different time points after tumor established (Figure 
4B and S4A). HCC cells gradually invaded into the 
surrounding connective tissues in the control group. 
However, the boundary between HCC cells and 
surrounding connective tissues appeared intact in the 
GPx3 over-expression group. Furthermore, according 
to 3D reconstructed images, we could clearly observe 
that more tumor cells invaded into the surrounding 
connective tissues in Z-axis in the control group as 
early as 2 weeks after innoculation (Figure 4C, Movie 
S1 and Movie S3). In the contrast, the invasiveness of 
HCC cells with over-expression of GPx3 was 
significantly inhibited (Figure 4C and S4B, Movie S2 
and Movie S4).  
GPx3 suppressed HCC invasiveness through 
inhibition of JNK-cJun-MMP2 signaling 
pathway in HCC cells, animal model and 
clinical samples 
Metalloproteinases (MMPs) are required to 
facilitate the degradation of extracellular matrix in the 
process of tumor invasion. Among the three 
commonly down-regulated subtypes of MMPs 
(MMP2, MMP7 and MMP9) in liver cancer, only 
MMP2 was most significantly suppressed upon GPx3 
over-expression (Figure 5A). It has been reported that 
MMP2 expression is regulated by MAP Kinase 
signaling pathway. In our study, we found that the 
nuclear translocation of JNK (one of MAP Kinases) 
was significantly inhibited upon over-expression of 
GPx3 (Figure 5B). Furthermore, the activation of JNK 
and its down-stream target c-Jun were significantly 
inhibited upon over-expression of GPx3 (Figure 5C). It 
suggested that the tumor suppressive function of 
GPx3 may be mediated through JNK-cJun-MMP2 
signaling pathway (Figure S5). 





Figure 3. Over-expression of GPx3 significantly suppressed migration, invasiveness and metastasis of HCC cells. (A) Over-expression of GPx3 significantly 
suppressed migration of HCC cells in wound healing assay. (B) Over-expression of GPx3 significantly suppressed invasiveness of HCC cells in Matrigel invasion assay, *P < 0.01. 
The error bar represented as mean ± SD. (C) Over-expression of GPx3 significantly inhibited intra-hepatic tumor spread in orthotopic nude mice liver cancer model (n = 6). (D) 
Over-expression of GPx3 significantly inhibited lung metastasis of HCC cells injected through tail vein of nude mice (n = 3). 





Figure 4. Real-time intravital imaging showed that over-expression of GPx3 significantly suppressed HCC invasiveness. (A) Ectopic nude mice liver cancer 
model with dorsal window chamber was established. (B) HCC cells gradually invaded into surrounding connective tissues at different time points in the control group. In the 
contrast, HCC cells with over-expression of GPx3 remained intact. Yellow arrow heads indicated invasive tumor cells. (C) Three-dimension reconstructed images showed that 
HCC cells invaded into surrounding connective tissues in Z-axis as early as 2 weeks after innoculation. However, the invasiveness of HCC cells with over-expression of GPx3 was 
significantly inhibited. 





Figure 5. The suppressive function of GPx3 may be mediated through inhibition of JNK-cJun-MMP2 signaling pathway. (A) Expression of MMP2 was most 
significantly suppressed upon GPx3 over-expression in HCC cells in protein (left panel) and mRNA level (right panel). (B) Nuclear translocation of JNK was significantly 
attenuated upon GPx3 over-expression in HCC cells. The error bar represented as mean ± SD. (C) Activation of JNK-cJun signaling pathway was significantly inhibited upon 
GPx3 over-expression in HCC cells. Clinically, MMP2 expression negatively correlated with GPx3 expression in tumor tissues collected from HCC patients during liver 
transplantation: (D) Western-blot (E) IHC staining. (F) The negative correlation between MMP2 and GPx3 expression was further validated in the clinical serial sections. (G) In 
orthotopic rat liver transplantation model with tumor development, the negative correlation between MMP2 and GPx3 expression was also confirmed. More intra-hepatic tumor 
spread was observed in small-for-size liver graft in which GPx3 was significantly down-regulated while MMP2 was up-regulated. The opposite trend could be observed in the 
whole graft. 




We further validated the results in the clinical 
samples of tumor tissues from 38 HCC patients who 
have undergone liver transplantation. We found that 
MMP2 expression negatively correlated with GPx3 
expression (Figure 5D, 5E, S6 and S7). Moreover, the 
negative correlation between GPx3 and MMP2 
expression in IHC staining was statistically significant 
(r = -0.558, P<0.001, Figure 5E, right panel) according 
to linear regression analysis. The negative correlation 
was also validated in distribution of GPx3 and MMP2 
in serial sections. We found that GPx3 was 
significantly down-regulated while the MMP2 was 
significantly up-regulated in the same area of serial 
sections (Figure 5F).  
In order to avoid the clinical confounding 
factors, we established a rat orthotopic liver 
transplantation model with tumor development. We 
found that intra-hepatic tumor metastasis was 
significantly higher in small-for-size liver graft 
compared with whole graft (Figure 5G). This finding 
is consistent with our previous study that 
small-for-size liver graft may be favorable for tumor 
growth [6, 21]. Moreover, GPx3 was significantly 
down-regulated while MMP2 was significantly 
up-regulated in small-for-size liver graft (Figure 5G, 
left panel). The opposite trend could be observed in 
the whole graft (Figure 5G, right panel). It implied 
that down-regulation of GPx3 and up-regulation of 
MMP2 may contribute to tumor progression in 
small-for-size liver graft. 
Discussion 
We identified that down-regulation of GPx3 in 
small-for-size liver graft was significantly associated 
with HCC invasiveness in a rat model and further 
found that lower plasma GPx3 was an independent 
predictor for poor overall survival of HCC patients 
after liver transplantation. Moreover, we found that 
GPx3 was not only a predictor for prognosis, but also 
suppressed HCC invasiveness through 
JNK-cJun-MMP2 signaling pathway. Therefore, in 
addition to prognostic value, GPx3 may possess the 
therapeutic potential targeting at HCC recurrence 
after liver transplantation. 
Although higher AFP level [22, 23], larger tumor 
size [24, 25], venous infiltration [22, 23], advanced 
pTNM stage [26], beyond UCSF [27] or Milan [23] 
criteria are normally applied as prognostic markers 
for tumor recurrence after liver resection, these factors 
were not identified as independent predictors for 
overall survival after liver transplantation in our 
study. It might be attributed to the different 
mechanisms of tumor recurrence between liver 
transplantation and resection. The whole diseased 
liver was completely removed in transplantation. The 
only source for tumor recurrence is the tumor cells 
remained in circulation or other organs. Tumor 
recurrence highly depends on the environmental 
factors in the newly implanted liver. Therefore, the 
plasma GPx3, which is negatively associated with 
inflammatory environment in the liver graft, was 
identified to be correlated with prognosis 
post-transplantation. Recently, a series of novel 
markers for HCC recurrence after liver 
transplantation were identified, such as CD147 [28], 
HOTAIR [29], YAP [30] and MALAT1 [31]. However, 
they may not possess the therapeutic effect to prevent 
tumor recurrence. GPx3 may possess both prognostic 
and therapeutic value for HCC patients after liver 
transplantation.  
The conventional animal study for investigation 
of tumor invasiveness always drew the conclusion 
based on the observation at end time point or 
sacrifice. However, the tumor invasiveness in a living 
animal is a dynamic process and could initiate at very 
early stage. Although the tumor cells labeled with 
bioluminescence could be kinetically detected, it 
cannot visualize intra-hepatic tumor invasion and 
illustrate the invasion process in a single cell level. 
Currently available optical techniques of functional 
imaging, such as MRI, PET and CT, are also limited by 
restricted penetration depth imposed by tissue 
turbidity, which avoids the possibility of utilizing 
high resolution microscope [13]. Real-time intravital 
imaging with dorsal window chamber enables us to 
kinetically observe the tumor behavior and directly 
see the tumor cells in a living animal. We could clearly 
observe that tumor cells gradually invaded into the 
surrounding connective tissue at different time points 
in a single cell level under confocal microscope. 
Furthermore, we could explore the process of tumor 
invasion in a 3-dimenssional view. Using this 
technique, we kinetically observed that 
over-expression of GPx3 significantly suppressed 
HCC invasiveness in a living animal. 
Matrix metalloproteinase family (MMPs) is 
required for the tumor cells to degrade the 
extracellular matrix and to facilitate tumor 
invasiveness [32]. Thus, the MMPs inhibitors were 
applied in many clinical trials for cancer therapy [33]. 
However, these trials have been proven disappointing 
so far [34]. It is probably due to that MMPs are 
involved at early stage of tumor progression [34, 35]. 
In our study, the real-time intravital imaging also 
showed that the HCC cells invaded into surrounding 
tissue as early as two weeks after innoculation. That 
could partially explain the failure of application of 
MMPs inhibitor in clinical trials with end-stage tumor 
[35]. Our study showed that the lower GPx3 level 
during one-week post-transplantation significantly 




correlated with tumor recurrence and poor survival of 
HCC patients. Therefore, application of GPx3 
administration at early phase post-operation may 
provide new therapeutic strategy for HCC patients 
after liver transplantation. 
In conclusion, we identified that 
down-regulation of GPx3 was associated with HCC 
invasiveness in a rat liver transplantation model. 
Clinically, plasma GPx3 was significantly lower in the 
patients with tumor recurrence after liver 
transplantation and the lower plasma GPx3 was 
identified as an independent predictor for poor 
overall survival. Moreover, over-expression of GPx3 
significantly suppressed migration, invasiveness and 
metastasis of HCC cells. Most importantly, the 
real-time intravital imaging has shown that 
over-expression of GPx3 kinetically suppressed HCC 
invasiveness in a living animal. Furthermore, the 
tumor suppressive function of GPx3 may be mediated 
through inhibition of JNK-cJun-MMP2 signaling 
pathway. Based on the advantage of the dual role of 
GPx3 in suppression of oxidative stress and liver 
cancer, the application of GPx3 administration may be 
a “one stone for two birds” strategy to attenuate 
hepatic IR injury and prevent tumor recurrence after 
liver transplantation. The suppressive role of GPx3 in 
inflammation in liver graft injury is worthwhile for 
further investigation. 
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